
Oncology
13 Mar 2025
Positive Survival Outcomes for Melanoma Brain Metastases in New Trial
A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.
Latest Journals
All JournalsCongress Reviews
All Congress ReviewsLatest Infographics
All InfographicsLatest Podcasts
All Podcasts
